Biogen (BIIB) announced topline results from the Phase 2 CELIA study evaluating diranersen; CELIA did not meet its primary endpoint assessing dose response for change from baseline on the Clinical Dementia Rating-Sum of Boxes at Week 76
- Based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development.
- VP says: "We are excited by these Phase 2 data, which give us the confidence to advance diranersen to registrational development".
Context
Biogen’s announcement regarding the Phase 2 CELIA study failing to meet its primary endpoint is significant, reflecting concerns about the trial's effectiveness. However, the company plans to move forward with diranersen based on encouraging biomarker and efficacy data, indicating that they see potential value despite the missed endpoint. This mixed result could impact investor sentiment, as it highlights both challenges and optimistic future prospects for the drug's development.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#BIOGEN IDEC INC#BIIB.US#EQUITIES#EU SESSION#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#BIOGEN INC#BIIB#US EQUITIES